Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : between 20 and 90 years old~* Histologically confirmed adenocarcinoma of the colon or the upper rectum~* Patients with resectable primary colon or upper rectal cancer and unresectable metastatic lesions.~* Patients with no primary cancer related symptoms.~* ECOG performance status of 0 - 2~* Appropriate organ functions (hepatic transaminases - less than 5 times the normal range; bilirubin - less than 2 times the normal range; creatinine serum - less than 1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than 1,500/µl)~* ASA score of \< 3~* An informed consent form has been signed by the patient.~Exclusion Criteria:~* The patient received adjuvant chemotherapy within the past 6 months.~* The patient received chemotherapy for metastatic colon cancer.~* The patient was planning to have curative surgery for the metastatic lesions.~* The primary cancer is unresectable.~* Patients with peritoneal carcinomatosis.~* Patients with mid and low rectal cancer (\< 10cm)~* Patients with primary tumor related complications such as intestinal obstruction, intractable bleeding, and perforation, that needs to be treated.~* ASA score of \> 4~* The patient has chronic hepatitis or cirrhosis. An asymptomatic HBV or HCV carrier can participate.~* Patients with an active infection, which need antibiotic therapy, during the randomization period.~* Pregnant or breastfeeding women~* Patients who were enrolled in another clinical trial during the time of enrollment (within the 28 day randomization period).~* Patients with another different malignant tumor during the past 5 years. Patients with treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy first without primary tumor resection (Type: EXPERIMENTAL): Patients will receive chemotherapy first without primary tumor resection.
- Primary tumor resection followed by chemotherapy (Type: ACTIVE_COMPARATOR): Patients will receive primary tumor resection followed by chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).